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Glucocorticoids are pleiotropic hormones, which are involved in almost every cellular, molecular and physiologic
network of the organism, and regulate a broad spectrum of physiologic functions essential for life. The cellular
response to glucocorticoids displays profound variability both in magnitude and in specificity of action. Tissue
sensitivity to glucocorticoids differs among individuals, within tissues of the same individual and within the same
cell. The actions of glucocorticoids are mediated by the glucocorticoid receptor, a ubiquitously expressed
intracellular, ligand-dependent transcription factor. Multiple mechanisms, such as pre-receptor ligand metabolism,
receptor isoform expression, and receptor-, tissue-, and cell type-specific factors, exist to generate diversity as well
as specificity in the response to glucocorticoids. Alterations in the molecular mechanisms of glucocorticoid receptor
action impair glucocorticoid signal transduction and alter tissue sensitivity to glucocorticoids. This review summarizes
the recent advances in our understanding of the molecular mechanisms determining tissue sensitivity to glucocorticoids
with particular emphasis on novel mutations and new information on the circadian rhythm and ligand-induced
repression of the glucocorticoid receptor.
Keywords: Glucocorticoid receptor, Glucocorticoid resistance, Glucocorticoid hypersensitivity, Glucocorticoid signal
transductionBackground
In humans, glucocorticoids are synthesized by the ad-
renal cortex and released following activation of the
hypothalamic-pituitary-adrenal (HPA) axis, and play an
important role in the maintenance of resting and stress-
related homeostasis. Named for their effects on glucose
metabolism, glucocorticoids are involved in almost every
cellular, molecular and physiologic network of the or-
ganism, and regulate a broad spectrum of physiologic* Correspondence: nnicolaides@bioacademy.gr
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article, unless otherwise stated.functions essential for life, including growth, reproduction,
cognition, behavior, cell proliferation and survival, as well
as immune, central nervous system (CNS) and car-
diovascular functions [1-3]. Given their powerful anti-
inflammatory and immunosuppressive actions, synthetic
glucocorticoids represent one of the most widely used
therapeutic compounds employed in the treatment of
acute and chronic inflammatory/autoimmune and lym-
phoproliferative disorders [1,3]. However, chronic expos-
ure to glucocorticoids in patients with such disorders
leads to multiple adverse effects. Sometimes glucocortic-
oid resistance of the affected organ or tissue may develop,
representing a major challenge for the treatment of these
conditions [4].
At the cellular level, the actions of glucocorticoids
are mediated by the human glucocorticoid receptortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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retinoic acid nuclear receptor superfamily of transcrip-
tion factors [2,5]. Consistent with the pleiotropic effects
of glucocorticoids, the hGR is ubiquitously expressed in
all human tissues and cells, and is necessary for life after
birth [6]. The hGR protein is encoded by exons 2–9 of
the hGR gene (located on chromosome 5) and is com-
posed of four distinct regions: the amino-terminal do-
main (NTD), the DNA-binding domain (DBD), the hinge
region and the ligand-binding domain (LBD) [2,5]. Alter-
native splicing of hGR precursor mRNA gives rise to 5
hGR protein subtypes that have been termed hGRα,
hGRβ, hGRγ, hGR-A and hGR-P. An additional cohort of
eight receptor proteins (hGRα-A, hGRα-B, hGRα-C1,
hGRα-C2, hGRα-C3, hGRα-D1, hGRα-D2, and hGRα-D3)
is produced by alternative translation initiation from hGR
mRNA [2,5,7]. hGRα-A is the classic full-length 777-amino
acid receptor that is generated from the first translation
initiation codon [2,5,7]. The other hGRα isoforms have
progressively shorter NTDs, possess both common and
unique properties and may differentially transduce the
glucocorticoid signal to target tissues depending on their
selective relative expression and inherent activities. All
translational isoforms have similar affinity for the ligand
and ability to bind to DNA, consistent with the presence of
a common LBD. However, they display differences in their
subcellular distribution, with hGRα-D residing constitu-
tively in the nucleus of cells, a fact that indicates that se-
quences in the NTD of the hGR may play an important
role in nuclear translocation, nuclear export and/or cyto-
plasmic retention of the receptor. In addition, these trans-
lational isoforms display significant differences in their
ability to regulate gene expression, with the hGRα-C iso-
forms being the most active, and the hGRα-D subtypes be-
ing the most “deficient” in their ability to transactivate
glucocorticoid-responsive genes [7]. Recent evidence sug-
gests that hGRα-C3 displays higher transcriptional activity
than the other hGRα isoforms, owing to increased recruit-
ment of coactivators at the promoter regions of target
genes [8]. In addition to the hGR isoforms generated by
alternative splicing or alternative initiation of translation,
four novel receptor variants with multiple amino acid re-
placements/truncation have been described [hGR NS-1,
hGR DL-1, hGR-S1 and hGR-S1 (−349A)] [9,10]. Their
functional role remains to be elucidated.
The hGR regulates gene expression by either trans-
criptional activation (transactivation) or transcriptional
repression (transrepression). Prior to binding to gluco-
corticoids, the hGR resides mostly in the cytoplasm
of cells as part of a large multiprotein complex [2,11].
Upon ligand-induced activation, the receptor undergoes
conformational changes that result in dissociation from
this multiprotein complex and translocation into the nu-
cleus, where it binds to glucocorticoid-response elements(GREs) in the promoter region of target genes [2,11,12].
The latter contain hexamer domains in an inverted palin-
drome arrangement separated by 3 base pairs in the regu-
latory regions of target genes and regulate their expression
positively or negatively through interaction with coactiva-
tors [12] or corepressors [2,11], respectively. Glucocorti-
coids may mediate anti-inflammatory effects via direct
binding of hGR to evolutionarily conserved negative GREs
(nGREs), which contain an inverted tetrameric palindrome
separated by 0–2 base pairs that is distinct from the classic
GREs [13]. The ligand-activated hGR can also modulate
gene expression independently of DNA-binding, by inter-
acting with other transcription factors, such as nuclear
factor-κB (NF-κB), activator protein-1 (AP-1), p53 and sig-
nal transducers and activators of transcription (STATs).
The interaction of hGR with the pro-inflammatory tran-
scription factors NF-κB and AP-1 inhibits their activity and
accounts for the major anti-inflammatory and immu-
nosuppressive effects of glucocorticoids [3]. Although the
transcriptional activity of hGR is primarily governed by lig-
and binding, post-translational modifications also play im-
portant roles. These covalent changes include methylation,
acetylation, nitrosylation, sumoylation, ubiquitination and
phosphorylation, and may affect receptor stability, subcel-
lular localization, as well as the interaction of hGR with
other proteins [11].
In addition to the above-described genomic actions,
glucocorticoids can induce some effects via the GR within
seconds or minutes. The non-genomic rapid glucocorticoid
actions appear to be mediated by membrane bound GRs,
which trigger the activation of kinase signaling pathways,
thus influencing many CNS and other tissue functions
[14]. On the other hand, the MR functions as the 2nd
glucocorticoid receptor in some tissues (e.g. limbic struc-
ture of the brain and adipose tissue), which do not express
the glucocorticoid-inactivating 11β-hydroxysteroid dehy-
drogenase 2, and cooperates with the classic GR to regulate
expression of common and/or distinct target genes [15].
The cellular response to glucocorticoids displays pro-
found variability both in magnitude and in specificity of
action [2,11]. Multiple mechanisms exist to generate
diversity, as well as specificity in the response to gluco-
corticoids, such as pre-receptor ligand metabolism, re-
ceptor isoform expression, and receptor-, tissue-, and
cell type-specific factors. Furthermore, recent findings
from in vitro and in vivo studies have demonstrated the
important new role of old molecules, such as the serum-
and glucocorticoid-inducible kinase 1 (SGK1) [16,17]
and FK506 -binding protein 51 (FKBP5) [18,19], in tissue
sensitivity to glucocorticoids and associated pathologic
conditions. In addition to protein-protein interactions, tis-
sue responsiveness to glucocorticoids has become more
complicated since the identification and functional cha-
racterization of hGR polymorphisms [20-24]. Interestingly,
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glucocorticoid sensitivity [25]. Any of the above-described
molecular mechanisms may lead to alterations in tissue
sensitivity to glucocorticoids, which may take the form of
glucocorticoid resistance or glucocorticoid hypersensitivity
and may be associated with significant morbidity (Table 1)
[26]. This review summarizes the recent advances in the
molecular mechanisms underlying tissue sensitivity to glu-
cocorticoids, with particular emphasis on novel mutations
and new information on the circadian rhythm of tissue
sensitivity to glucocorticoids, and ligand-induced repres-
sion of the glucocorticoid receptor.
Pathologic natural hGR gene mutations causing primary
generalized glucocorticoid resistance or Chrousos
syndrome
Natural hGR gene mutations impair the molecular
mechanisms of hGR action and alter tissue sensitivity to
glucocorticoids [27-49]. The majority of the natural hGR
mutations described to date are associated with Chrou-
sos syndrome, a rare, familial or sporadic genetic condi-
tion characterized by generalized, partial, target-tissue
insensitivity to glucocorticoids (Figure 1). Affected sub-
jects have compensatory activation of the HPA axis and
elevations in circulating cortisol and adrenocorticotropic
hormone (ACTH) concentrations throughout the 24-
hour period without, however, any clinical manifesta-
tions of hypercortisolism. The excess ACTH secretion
results in adrenal hyperplasia, and increased production
of adrenal steroids with mineralocorticoid activity [corti-
sol, deoxycorticosterone (DOC) and corticosterone] and/
or androgenic activity [androstenedione, dehydroepian-
drosterone (DHEA) and DHEA-sulfate (DHEAS)], and
the corresponding clinical phenotype (Tables 2 and 3)
[27-45,47-49].
We have recently described a new case of Chrousos
syndrome caused by a novel, heterozygous, point mu-
tation (V423A) in the DBD of the hGRα, and inves-
tigated the molecular mechanisms through which the
hGRαV423A affects glucocorticoid signal transduction.
Compared with the wild-type receptor, the mutant recep-
tor hGRαV423A demonstrated a significant reductionTable 1 Expected clinical manifestations in tissue-specific glu
Target tissue Glucocorticoid hypersensitivity = Glucocorticoi
Central nervous system Insomnia, anxiety, depression, defective cognition
Liver + Gluconeogenesis, + lipogenesis
Fat Accumulation of visceral fat (metabolic syndrome
Blood vessels Hypertension
Bone Stunted growth, osteoporosis
Inflammation/immunity Immune suppression, anti-inflammation, vulnerabi
infections and tumors
Modified from Reference [30].(72%) in its ability to transactivate glucocorticoid-
responsive genes, impaired ability to bind to GREs and a
marked delay (2.6-fold) in the time required to translocate
into the nucleus. However, the hGRαV423A did not exert
a dominant negative effect upon the wild-type hGRα, had
a similar affinity for the ligand, and displayed a normal
interaction with the glucocorticoid receptor-interacting
protein-1 (GRIP1) coactivator (Figure 2) [47].
Structural biology studies using computer-based cre-
ation of the 3-dimentional structure of the hGR DBD
harboring the V423A mutation showed that the V423A
substitution alters the hydrophobic nature of the first
zinc finger of the hGRα DBD, and permits water to dif-
fuse into the nearby zinc-binding site. The hydropho-
bic valine (V) at position 423 in the hGRα DBD shields
the four zinc-binding cysteines (C421, C424, C438, and
C441) from water, thereby creating a hydrophobic envir-
onment. Replacement of valine (V) by alanine (A) at this
position destroys the hydrophobic environment and per-
mits water to diffuse into the ion-binding region of the
protein, where it is captured by hydrogen bonds to C424
and C441, and reduces their affinity for binding to GREs
[47]. These findings expand our knowledge on the pre-
viously described molecular mechanisms of action of
natural hGR mutants, and may explain the differences
observed in the clinical phenotype of subjects with
Chrousos syndrome [27-45,47-49].
CLOCK-mediated acetylation of hGR: Implications for
circadian rhythm-mediated regulation of glucocorticoid
action in target tissues
In humans, circulating cortisol concentrations are tightly
regulated by the central components of the HPA axis
and fluctuate naturally in an ultradian and circadian fash-
ion, reaching their zenith in the early morning and their
nadir in the late evening [1]. Stavrera et al. showed that ul-
tradian glucocorticoid pulses resulted in dynamic associ-
ation and dissociation of GR with the promoters of target
genes leading to cyclic GR-mediated transcriptional regu-
lation [50]. Interestingly, this coupling was not observed
upon exposure of cells to synthetic glucocorticoids, since
these were shown to prevent the dissociation of GR fromcocorticoid resistance or hypersensitivity
d excess Glucocorticoid resistance = Glucocorticoid deficiency
Fatigue, somnolence, malaise, defective cognition
Hypoglycemia, resistance to diabetes mellitus
) Loss of weight, resistance to weight gain
Hypotension
lity to certain + Inflammation, + autoimmunity, + allergy
Figure 1 Schematic representation of the known mutations of the hGR gene causing Chrousos syndrome. DBD: DNA-binding domain;
LBD: ligand-binding domain; NTD: amino terminal domain.
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dings at the level of target tissues, recent studies have
investigated the molecular mechanisms underlying gluco-
corticoid oscillations [51-53]. Walker et al. employed a
mathematical model to study how the HPA axis supports
ultradian glucocorticoid fluctuations [51]. They demon-
strated that the pituitary-adrenal axis can produce ACTH
and glucocorticoid ultradian oscillations in the presence of
constant levels of CRH [51]. Their results were further
confirmed by in vivo studies [53]. Indeed, a constant CRH
input in the pituitary-adrenal axis resulted in physiological
ultradian fluctuations of ACTH and glucocorticoids,Table 2 Clinical manifestations and diagnostic evaluation of p
Chrousos Syndrome
Clinical presentation
Apparently normal glucocorticoid function
Asymptomatic
Hypoglycemia





Children: Ambiguous genitalia at birth*, premature adrenarche,
precocious puberty
Females: Acne, hirsutism, male-pattern hair loss, menstrual irregularities,
oligo-anovulation, infertility
Males: Acne, hirsutism, oligospermia, adrenal rests in the testes, infertility
Increased HPA axis activity (CRH/ACTH hypersecretion)
Anxiety
Adrenal rests
Modified from References [28] and [29].
*This is the only case of ambiguous genitalia documented in a child with 46,XX karyotwhereas higher levels of CRH led to the disruption of the
oscillating patterns [53]. On the other hand, the circadian
secretion of cortisol is generated by an evolutionary con-
served molecular ‘clock’, the circadian clock system, which
consists of central and peripheral components [54,55].
The central clock system, located in the suprachiasmatic
nucleus (SCN) of the hypothalamus, acts as the ‘master’
oscillator and generator of the body’s circadian rhythm
under the strong influence of the light/dark input from
the eyes [50,54,55]. Interestingly, the neurons of SCN do
not express GR; therefore glucocorticoid feedback does
not directly affect the activity of the master SCN clock.rimary generalized glucocorticoid resistance or
Diagnostic evaluation
Absence of clinical features of Cushing syndrome
Normal or elevated plasma ACTH concentrations
Elevated plasma cortisol concentrations
Increased 24-hour urinary free cortisol excretion
Normal circadian and stress-induced pattern of cortisol and ACTH secretion
Resistance of the HPA axis to dexamethasone suppression
Thymidine incorporation assays: Increased resistance to dexamethasone-
induced suppression of phytohemaglutinin-stimulated thymidine
incorporation compared to control subjects
Dexamethasone-bindings assays: Decreased affinity of the glucocorticoid
receptor for the ligand compared to control subjects
Molecular studies: Mutations/deletions of the glucocorticoid receptor
ype who also harbored a heterozygous mutation of the 21-hydroxylase gene.
Table 3 Mutations of the human glucocorticoid receptor gene causing primary generalized glucocorticoid resistance
or hypersensitivity
Mutation position
Author (Reference) cDNA Amino acid Molecular mechanisms Genotype Phenotype
Chrousos et al. [27] 1922 (A→ T) 641 (D→ V) Transactivation ↓ Homozygous Hypertension
Hurley et al. [32] Affinity for ligand ↓ (× 3) Hypokalemic alkalosis
Nuclear translocation: 22 min
Abnormal interaction with GRIP1
Karl et al. [33] 4 bp deletion in hGRα number: 50% of control Heterozygous Hirsutism
exon-intron 6 Inactivation of the affected allele Male-pattern hair-loss
Menstrual irregularities
Malchoff et al. [34] 2185 (G→ A) 729 (V→ I) Transactivation ↓ Homozygous Precocious puberty
Affinity for ligand ↓ (× 2) Hyperandrogenism
Nuclear translocation: 120 min
Abnormal interaction with GRIP1
Karl et al. [31] 1676 (T→ A) 559 (I→ N) Transactivation ↓ Heterozygous Hypertension
Kino et al. [35] Decrease in hGR binding sites Oligospermia
Transdominance (+) Infertility
Nuclear translocation: 180 min
Abnormal interaction with GRIP1
Ruiz et al. [36] 1430 (G→ A) 477 (R→ H) Transactivation ↓ Heterozygous Hirsutism
Charmandari et al. [41] No DNA binding Fatigue
Nuclear translocation: 20 min Hypertension
Ruiz et al. [36] 2035 (G→ A) 679 (G→ S) Transactivation ↓ Heterozygous Hirsutism
Charmandari et al. [41] Affinity for ligand ↓ (× 2) Fatigue
Nuclear translocation: 30 min Hypertension
Abnormal interaction with GRIP1
Mendonca et al. [37] 1712 (T→ C) 571 (V→ A) Transactivation ↓ Homozygous Ambiguous genitalia
Affinity for ligand ↓ (× 6) Hypertension
Nuclear translocation: 25 min Hypokalemia
Abnormal interaction with GRIP1 Hyperandrogenism
Vottero et al. [38] 2241 (T→ G) 747 (I→M) Transactivation ↓ Heterozygous Cystic acne
Transdominance (+) Hirsutism
Affinity for ligand ↓ (× 2) Oligo-amenorrhea
Nuclear translocation ↓
Abnormal interaction with GRIP1
Charmandari et al. [40] 2318 (T→ C) 773 (L→ P) Transactivation ↓ Heterozygous Fatigue
Transdominance (+) Anxiety
Affinity for ligand ↓ (× 2.6) Acne
Nuclear translocation: 30 min Hirsutism
Abnormal interaction with GRIP1 Hypertension
Charmandari et al. [42] 2209 (T→ C) 737 (F→ L) Transactivation ↓ Heterozygous Hypertension
Transdominance (time-dependent) (+) Hypokalemia
Affinity for ligand ↓ (× 1.5)
Nuclear translocation: 180 min
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Table 3 Mutations of the human glucocorticoid receptor gene causing primary generalized glucocorticoid resistance
or hypersensitivity (Continued)
McMahon et al. [43] 2 bp deletion 773 Transactivation ↓ Homozygous Hypoglycemia
at nt 2318-9 Affinity for ligand: absent Fatigability with feeding
No suppression of IL-6 Hypertension
Nader et al. [44] 2141 (G→ A) 714 (R→Q) Transactivation ↓ Heterozygous Hypoglycemia
Transdominance (+) Hypokalemia
Affinity for ligand ↓ (× 2) Hypertension
Nuclear translocation ↓ Mild clitoromegaly
Abnormal interaction with GRIP1 Advanced bone age
Precocious pubarche
Zhu Hui-juan et al. [45] 1667 (G→ T) 556 (T→ I) Not studied yet Heterozygous Adrenal incidentaloma
Charmandari et al. [46] 1201 (G→ C) 401 (D→ H) Transactivation ↑ Heterozygous Visceral obesity
Transdominance (+) Hypercholesterolemia
Affinity for ligand: N Hypertriglyceridemia
Nuclear translocation: N Hypertension
Interaction with GRIP1: N Diabetes type 2
Roberts et al. [47] 1268 (T→ C) 423 (V→ A) Transactivation ↓ Heterozygous Fatigue
Affinity for ligand: N Anxiety
No DNA binding Hypertension
Nuclear translocation: 35 min
Interaction with GRIP1: N
Nicolaides et al. [48] 1724 (T→ G) 575 (V→ G) Transactivation ↓ Heterozygous Melanoma
Transrepression ↑ Asymptomatic daughters
Affinity for ligand ↓ (× 2)
Nuclear translocation ↓
Abnormal interaction with GRIP1
Modified from References [29] and [30].
Numbers in the parentheses following authors’ names indicate the corresponding references.
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gans and tissues, including the central nervous system
outside the SCN, acts generally as a ‘slave’ clock under the
regulation of the central SCN clock, by as yet unknown
mechanism(s) [54-56]. Both clocks communicate with
each other and generate circadian rhythmicity by the co-
ordinated activation/inactivation of self-oscillating tran-
scription factors. Central among them are the circadian
locomotor output cycle kaput (CLOCK) and its hetero-
dimer partner brain-muscle-arnt-like protein 1 (BMAL1)
[54-56].
We have recently demonstrated that CLOCK physic-
ally interacts with the LBD of the hGR and suppresses
the hGR-induced transcriptional activity by acetylating
multiple lysine residues (480, 492, 494, and 495) in the
hinge region of the receptor. This post-translational mo-
dification attenuates the binding of hGR to GREs and its
ability to influence glucocorticoid-responsive gene ex-
pression. Furthermore, the expression of glucocorticoid-responsive genes fluctuated in a circadian fashion, mir-
roring in reverse phase the Clock/Bmal1 expression [57].
These findings indicate that CLOCK/BMAL1 is a reverse-
phase negative regulator of glucocorticoid action in target
tissues, antagonizing the biologic actions of diurnally fluc-
tuating circulating glucocorticoids and providing a local
target tissue counter-regulatory feedback loop to the cen-
tral clock influence on the HPA axis [57]. As a result,
tissue sensitivity to glucocorticoids is decreased in the
morning (when circulating cortisol concentrations are ele-
vated) and increased in the evening and early night (when
cortisol concentrations reach their nadir) (Figure 3).
In addition to these in vitro findings, we examined the
acetylation status of hGR and the expression of clock-
related and glucocorticoid-responsive genes in vivo and
ex vivo, using peripheral blood mononuclear cells from
healthy adult volunteers [58]. The levels of acetylated hGR
were higher in the morning and lower in the evening, mir-
roring the fluctuations of circulating cortisol concentrations
Figure 2 Μolecular mechanisms through which the natural mutant receptor hGRαV423A causes Chrousos syndrome. Both the wild-type
hGRα and the mutant hGRαV423A reside in the cytoplasm in the absence of ligand by forming a heterocomplex with heat shock proteins (HSP)
and FKBP51 (FKBP). Upon binding to ligand, the wild-type hGRα dissociates from the heterocomplex partners and translocates into the nucleus,
while this process of the mutant hGRαV423A is significantly delayed. The wild-type hGRα stimulates or represses the transcriptional activity of
glucocorticoid-responsive genes by attracting to GRE DNA several coactivators including the glucocorticoid receptor-interacting protein 1 (GRIP-1), or
by interacting with other transcription factors, such as NF-κB and activator protein-1 (AP-1). The hGRαV423A demonstrates reduced transactivation
activity due to decreased ability to interact with GREs, while its activity to repress the transcriptional activity of other transcription factors is preserved.
The hGRαV423A does not exert a dominant negative effect upon the wild type-induced transactivation of glucocorticoid-responsive genes. WT: wild-type
human glucocorticoid receptor; V423A: human glucocorticoid receptor V423A; HSP: heat shock proteins; FKBP: immunophilins; GRIP-1: glucocorticoid
receptor-interacting protein 1; p65: transcription factor p65; p50: transcription factor p50.
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genes tested responded as expected to hydrocortisone,
however, some of these genes did not show the expected
diurnal mRNA fluctuations in vivo. Instead, their mRNA
did not oscillate in the absence of endogenous gluco-
corticoid, indicating that circulating cortisol might pre-
vent circadian GR acetylation-dependent effects in some
glucocorticoid-responsive genes in vivo. These findings
suggest that peripheral CLOCK-mediated circadian acetyl-
ation of the hGR functions as a target-tissue, gene-specific
counter-regulatory mechanism to the actions of diurnally
fluctuating cortisol, effectively decreasing tissue sensitivity
to glucocorticoids in the morning and increasing it in the
evening and early night [58]. Furthermore, in another re-
cent study that determined the mRNA expression of ~190
hGR action-regulating and glucocorticoid-responsive ge-
nes in subcutaneous fat biopsies obtained from 25 obese
subjects, circulating cortisol concentrations in the evening
were more important in regulating the mRNA expressionof glucocorticoid-responsive genes than those in the
morning [59]. Therefore, it appears that the higher tis-
sue sensitivity to glucocorticoids in the evening, owing
to reduced hGR acetylation by CLOCK, underlies the
stronger effect of elevated circulating cortisol concen-
trations on the expression of glucocorticoid-regulated
genes in the evening and early night.
In line with our in vitro, in vivo and ex vivo results,
Lamia et al. recently showed that CRY1 and CRY2 inter-
acted with the GR in a ligand-dependent fashion, leading
to direct inhibition of GR-mediated transactivation of
glucocorticoid-responsive genes [60]. Interestingly, this
CRY-GR interaction did not affect the transrepressing
actions of GR on many inflammatory genes, indicating
that cryptochromes, when interact with the GR, could
influence the expression of a separate group of GR target
genes. This dissociation of the transactivating and trans-
repressing activities of the GR might reduce the frequency
of the undesirable metabolic effects during long-term
Figure 3 CLOCK-mediated gene-specific regulation of glucocorticoid action in peripheral target tissues. Circulating cortisol concentrations in
humans fluctuate diurnally, as indicated in the top panel. The expression of glucocorticoid-target genes is also expected to fluctuate depending on the
changes of circulating cortisol concentrations. However, this diurnal fluctuation of gene expression is suppressed through acetylation of GR by locally
expressed CLOCK/BMAL1 heterodimers, possibly functioning as a local counter-regulatory feedback loop to the circulating glucocorticoids. Thus, high
levels of acetylated GR in the morning are associated with low target-tissue sensitivity to glucocorticoids and vice versa in the evening and early night.
Modified from Reference [56].
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over, a very recent study demonstrated that CLOCK/
BMAL1 reduced both maximal GR transactivation of tar-
get genes and the efficacy of the receptor to increase the
transcription rate of glucocorticoid-responsive genes. On
the other hand, the PER1/CRY1 complex reduced the
maximal GR transactivation, but not the efficacy of the re-
ceptor, suggesting that both elements of the positive and
negative arm of the clock system repress GR transcrip-
tional activity [61].
The circadian clock system and the HPA axis regulate
the activity of one another through multilevel interac-
tions to ultimately coordinate homeostasis against the
day/night change and various unforeseen random in-
ternal and external stressors. Uncoupling of or dysfunc-
tion in either system alters internal homeostasis and
causes pathologic changes virtually in all organs and tis-
sues, including those responsible for intermediary metab-
olism and immunity [62]. Disrupted coupling of cortisol
secretion and target tissue sensitivity to glucocorticoidsmay account for i) the development of central obesity and
the metabolic syndrome in chronically stressed individ-
uals, whose HPA axis circadian rhythm is characterized by
blunting of the evening decreases of circulating glucocor-
ticoids, as a result of enhanced input of higher centers
upon the hypothalamic paraventricular nucleus secretion
of CRH and AVP; and ii) the increased cardiometabolic
risk and increased mortality of rotating shift workers or
subjects exposed to frequent jet lag because of traveling
across time zones [56,63]. In addition, given that tissue
sensitivity to glucocorticoids is increased in the evening,
clinicians should avoid the administration of high doses
of glucocorticoids for the treatment of adrenal insuffi-
ciency or congenital adrenal hyperplasia at night, because
they increase the possibility of glucocorticoid-related side
effects.
At pharmacological concentrations, the transactiva-
tional activity of glucocorticoids is correlated with the
side effects of these steroids, while their transrepressive
activity is associated mostly with their beneficial anti-
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regulate these two major class actions of glucocorticoids,
administration of these steroids at a specific period of
the circadian cycle might increase their pharmacological
efficacy, while at the same time reduce their unwanted
side effects [62].
Ligand-induced down-regulation (repression) of hGR
gene expression
Glucocorticoids are among the most potent and effective
agents for treating inflammatory diseases and hematologic
malignancies. However, a number of patients are often re-
sistant to treatment with glucocorticoids [1-4]. Therefore,
it is important to determine the molecular mechanisms
underlying this phenomenon in order to adequately treat
patients with these disorders.
Recent studies investigated the molecular mechanisms
responsible for repression of hGR gene transcription by
glucocorticoids. They demonstrated that glucocorticoid
treatment resulted in a rapid decrease in nascent hGR
RNA, with maximal repression being sustained for 6 to
8 h. They also identified a functional nGRE in exon 6 of
the hGR gene, which played an important role in the re-
pression of the hGR gene. Upon ligand-induced activation,
the hGR bound to the nGRE on exon 6 and recruited
NCoR1 (nuclear receptor corepressor) and HDAC3 (his-
tone deacetylase 3) to the promoter-proximal region,
thereby forming a repression complex and inhibiting hGR
transcription [64]. These findings indicate that the hGR
concentration can be down-regulated coordinately with
excess ligand, regardless of the combinatorial associations
of tissue-specific transcription factors. Therefore, although
glucocorticoid-induced down-regulation of hGR repre-
sents a mechanism for maintaining glucocorticoid homeo-
stasis in normal cells, it appears to have the potential to
limit the therapeutic response to glucocorticoids in in-
flammatory and malignant conditions. As a result, long-
term glucocorticoid treatment in patients with the above
disorders may lead to constitutive hGR transrepression
and glucocorticoid resistance.
In addition to glucocorticoid-induced down-regulation
of hGR, the expression of the receptor has been shown
to be influenced by epigenetic modifications which oc-
curred in the context of gene-environment interactions.
In their pioneering study, Weaver and collaborators
demonstrated that maternal behavior had a pivotal role
in stress responses of offspring. Indeed, rats exposed to
low levels of pup licking and grooming (LG) and arched-
back nursing (ABN) by their mothers, had increased
methylation of the 17 promoter of the GR gene, leading
to decreased levels of GR in the hippocampus and altered
response of the HPA axis to stressors [65]. This epigenetic
alteration of GR expression could also be involved in
drug-induced glucocorticoid resistance. Moreover, GRprotein levels were found to be reduced by micro-RNAs
(miRs), such as miR-18a [66], −18 and -124a [67] in neur-
onal tissues. Uchida et al. used Fischer 344 (F344) rats, a
well-known stress-hyperresponsive model, and showed
that this strain, upon a 14-day repeat restrain stress, had
increased levels of miR-18a and decreased GR protein ex-
pression in the PVN, compared with control Sprague–
Dawley (SD) rats [66]. Further studies have supported the
implication of microRNAs, specifically miR-18 and -124a,
in brain responsiveness to glucocorticoids. Both miR-18
and -124a down-regulated the GR, establishing their crit-
ical role in the regulation of glucocorticoid responsiveness
of the brain [67]. On the other hand, the specific down-
regulation of the GR in newborn hippocampal cells, using
viral-mediated RNA-interference in vivo, increased their
neuronal differentiation and migration, as well as their
basal excitability. These morphological and functional al-
terations of hippocampal cells resulted in impairments in
memory consolidation [68]. Therefore, blockade of select-
ive GR-dependent processes in brain would be therapeut-
ically beneficial. Zalachoras et al. demonstrated that the
non-steroidal GR ligand 1H-pyrazolo[3,4-g]hexahydroiso-
quinoline or C108297 selectively modulated GR activity in
the brain by suppressing CRH gene expression while en-
hancing GR-dependent memory consolidation by act-
ing as a unique GR modulator [69]. In contradistinction,
C108297 antagonized GR-mediated reduction in neuro-
genesis in the hippocampus following long-term admi-
nistration of glucocorticoids [69]. Thus, C108297 has a
potential to selectively abrogate pathogenic processes as-
sociated with GR in the brain, while retaining some bene-
ficial actions of this receptor.
Conclusions
The glucocorticoid receptor is a ubiquitously expressed
intracellular, ligand-dependent transcription factor, which
mediates the action of glucocorticoids and influences phy-
siologic functions essential for life. The traditional view
that glucocorticoids exert their diverse effects through one
receptor protein has changed dramatically over the last
two decades with the discovery of multiple hGR isoforms
arising from the single hGR gene. hGR subtypes with
unique expression and gene regulatory profiles are gener-
ated by alternative splicing of the nascent transcript, alter-
native translation initiation of the mature mRNA, and
post-translational modifications of the receptor protein.
The capacity of a cell to generate dozens of hGR isoforms
that control specific sets of genes and/or differentially
regulate common sets provides enormous potential for
signaling diversity. Further contributing to the tissue- and
cell-specific effects of glucocorticoids is the potential for
these isoforms to heterodimerize with each other and
cross-talk with other signaling molecules. The com-
binatorial nature of glucocorticoid signaling pathways
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ant implications for many critical biological processes and
may account for the alterations in tissue sensitivity to glu-
cocorticoids, as well as the variations in response to gluco-
corticoid treatment documented in clinical practice. A
greater understanding of the role that hGR heterogeneity
plays in the cellular response to glucocorticoids should aid
in the development of new glucocorticoid compounds
with selective activities that may offer the prospect of an
improved outcome with lesser side effects.
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